findings, mice lacking a functional A-type lamin gene (Lmna) develop an EDMD-like syndrome soon after birth and die within 6 weeks of cardiovascular disease. A recent publication by Chen et al. (2012) reports the remarkable finding that down- regulation of Sun1 expression in Lmna- deficient mice significantly extended their life span along with amelioration of cardiac pathology. Thus, LINC complexes could represent viable therapeutic targets for the treatment of certain types of stri- ated muscle disease and perhaps other laminopathies. The insights that Sosa et al. now provide into the molecular details of LINC complex assembly suggest strategies for the design of drugs that could interfere with SUN-KASH inter- actions. This convergence of structural biology and mouse genetics may provide the foundation for novel interventions in muscular dystrophy and heart disease. REFERENCES Burke, B., and Roux, K.J. (2009). Dev. Cell 17, 587–597. Chen, C.-Y., Chi, Y.-H., Mutalif, R.A., Starost, M.F., Myers, T.G., Anderson, S.A., Stewart, C.L., and Jeang, K.-T. (2012). Cell 149, 565–577. Ding, X., Xu, R., Yu, J., Xu, T., Zhuang, Y., and Han, M. (2007). Dev. Cell 12, 863–872. Hiraoka, Y., and Dernburg, A.F. (2009). Dev. Cell 17, 598–605. Ketema, M., Wilhelmsen, K., Kuikman, I., Janssen, H., Hodzic, D., and Sonnenberg, A. (2007). J. Cell Sci. 120, 3384–3394. Luxton, G.W., Gomes, E.R., Folker, E.S., Vintinner, E., and Gundersen, G.G. (2010). Science 329, 956–959. Mislow, J.M., Holaska, J.M., Kim, M.S., Lee, K.K., Segura-Totten, M., Wilson, K.L., and McNally, E.M. (2002). FEBS Lett. 525, 135–140. Sosa, B.A., Rothballer, A., Kutay, U., and Schwartz, T.U. (2012). Cell 149, this issue, 1035– 1047. Vander Heyden, A.B., Naismith, T.V., Snapp, E.L., Hodzic, D., and Hanson, P.I. (2009). Mol. Biol. Cell 20, 2661–2672. Zhou, Z., Du, X., Cai, Z., Song, X., Zhang, H., Mizuno, T., Suzuki, E., Yee, M.R., Berezov, A., Murali, R., et al. (2012). J. Biol. Chem. 287, 5317– 5326. Ironing Out Cell Death Mechanisms John C. Reed 1, * and Maurizio Pellecchia 1 1 Sanford-Burnham Medical Research Institute, La Jolla, CA 92037, USA *Correspondence: jreed@sanfordburnham.org DOI 10.1016/j.cell.2012.05.009 Historically, key cellular regulators of diverse physiological processes have been uncovered by studying the mechanisms by which chemical entities produce interesting biological pheno- types. In this issue, Dixon et al. interrogate compounds that selectively kill oncogene-express- ing cells, providing support for the existence of an iron-requiring, regulated form of cell death, ferroptosis. Various forms of regulated cell death have been identified, including apoptosis, necroptosis, paraptosis, parthanoptosis, pyroptosis, and autophagic cell death. In this issue, Stockwell and colleagues propose the existence of ferroptosis, an iron-dependent form of cell death (Dixon et al., 2012). Ferroptosis requires iron-dependent production of reactive oxygen species (ROS), involves nicotin- amide adenine dinucleotide phosphate (NADPH)-dependent oxidases and lipid peroxidation, and is associated morpho- logically with the presence of shrunken, electron-dense mitochondria (Figure 1). Distinguishing it from many other forms of regulated cell death, ferroptosis does not require caspases (mediators of apoptosis and pyroptosis), ATP depletion or mitochondrial ROS generation (media- tors of necroptosis), Bax/Bak (essential mediators of mitochondrial outer mem- brane permeabilization, MOMP), or eleva- tions in intracellular Ca 2+ . Ferroptosis was uncovered while seeking an understanding of the mecha- nism underlying the activity of erastin, a small molecule that selectively kills cells expressing oncogenic mutants of RAS (Dolma et al., 2003). This quinazo- line compound binds certain voltage- dependent anion channels (VDACs) on the mitochondrial outer membrane. Moreover, short hairpin RNA (shRNA) reagents targeting VDAC2 and VDAC3 rescue oncogenic RAS-expressing tumor cells from erastin (Yagoda et al., 2007; Yang and Stockwell, 2008). In the current paper, Dixon et al. (2012) show that erastin binds the subunit of cell surface amino acid transporters that import cystine, which then presumably causes reductions in glutathione, sensitizing cells to ROS. Evidence that cystine transport is critical to the mechanism of erastin includes data from experiments that either pharmacologically bypass erastin-induced cysteine transport block or that block cysteine transport with other compounds such as sulfasalazine and glutamate. The authors also sensi- tized tumor cells to erastin by shRNA- mediated knockdown of a subunit (SLCA11) of amino acid transporters Cell 149, May 25, 2012 ª2012 Elsevier Inc. 963